ALACHUA, Fla.--(BUSINESS WIRE)--RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a provider of orthopedic and other biologic implants, celebrated the ground breaking of its new 41,165-square-foot Logistics and Technology Center on Monday, Jan. 7.
RTI, which is headquartered in Alachua, Fla., is one of the leading providers of sterile biologic implants for patients around the world. Its Logistics and Technology Center, a $14 million investment, will be home to the company’s research and development offices and laboratories, clean rooms, warehouse, shipping and finished implants and other support functions. In addition, the new facility will include space for production of RTI’s forthcoming map3™ cellular allogeneic bone grafts.
“RTI began operations in 1998 when it spun off from the University of Florida Tissue Bank. At that time, our offices, labs and clean rooms occupied approximately 45,000 square feet of total space in Progress Corporate Park, housing about 200 people,” said Brian K. Hutchison, RTI president and CEO. “Today we have more than 700 employees globally. This new facility represents the continued growth and expansion of our company and allows us room for future growth.”
The Logistics and Technology Center, along with the company’s recent acquisition of a 15,425 square foot office building in the park, will expand RTI’s total occupied space to about 200,000 square feet.
“At RTI, we are committed to supporting the communities in which we operate and participating in the economic development of our regions,” said Hutchison. “We are excited to expand our facilities in Alachua, Fla. and are glad to be a part of a community that is focused on fostering innovation and success.”
Occupancy of RTI’s Logistics and Technology Center is expected in early 2014. The project is managed by Charles Perry Partners, Inc. Other groups that have been instrumental include Affiliated Engineers, Causseaux, Hewett, & Walpole, Inc., the City of Alachua, RS&H and Gyllstrom Architecture.
About RTI Biologics Inc.
RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and xenograft tissue for transplantation through extensive testing and screening, precision shaping and using proprietary, validated processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.
RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. These processes — BioCleanse®, Tutoplast® and Cancelle™ SP DBM — have a combined record of more than four million implants distributed with zero incidence of implant-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.
RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.
Forward Looking Statement
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's website at www.rtix.com or the SEC's website at www.sec.gov.
High-resolution photos available upon request.